Abstract 168P
Background
It is important to predict prognosis in patients with advanced gastric cancer receiving chemotherapy. Several studies have reported that Glasgow prognostic score (GPS), which was based on serum albumin (Alb) and C-reactive protein (CRP), was associated with poor prognosis in many cancers. However, it is unclear whether GPS has prognostic value when patients receive Irinotecan, which is a key drug of advanced gastric cancer.
Methods
We conducted a retrospective multicenter study and investigated association between efficacy and GPS in patients who received irinotecan monotherapy between January 2010 and December 2017. All patients had to receive fluoropyrimidine and platinum as prior therapy. GPS was identified that GPS 0 was CRP ≤1.0 mg/dL and Alb ≥3.5 g/dL, GPS 1 was CRP >1.0 mg/dL or Alb <3.5 g/dL, and GPS 2 was CRP >1.0 mg/dL and Alb <3.5 g/dL.
Results
There were 174 patients at 8 centers included in this study. The number of patients with GPS 0/1/2 was 76/56/42, respectively. In GPS 0/1/2 patients, performance status (0-1/2≤), treatment line 2nd/3rd or later, and HER2 status were significantly different among them(p < 0.01). As for safety, there was no significant difference among GPS 0/1/2 patients. In GPS 0/1/2 patients, median PFS were 3.7/2.8/2.0 months (p < 0.01), median OS were 11.9/7.2/6.7 months (p < 0.01), respectively. In multivariate analysis, GPS was associated with shorter PFS (GPS 0 vs 1/0vs 2 : HR 1.180/2.378, 95%C.I. 0.793-1.758/1.405-4.024, p = 0.414/0.001), and shorter OS (GPS 0 vs 1/0vs 2 : HR 1.520/2.529, 95%C.I. 1.002-2.305/1.518-4.213, p = 0.049/<0.001).
Conclusions
In this analysis, GPS might be a predictive and prognostic factor in treatment with irinotecan monotherapy for patients with AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yoshito Komatsu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract